Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial
Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial
复制标题
DOI：
10.1161/circulationaha.111.018259
复制
发表时间：
2011-08-02
期刊：
影响因子：
37.8
通讯作者：
Kastelein, John J. P.
中科院分区：
文献类型：
--
作者：
Barter, Philip J.;Rye, Kerry-Anne;Kastelein, John J. P.
高密度脂蛋白在体外具有抗糖尿病的特性。此外，伴随胆固醇酯转移蛋白遗传缺陷的高密度脂蛋白水平升高与血糖水平降低相关。我们现在调查的影响，葡萄糖稳态的抑制胆固醇酯转移蛋白torcetrapib.Methods和结果的事后分析的血脂水平管理的调查，以了解其在动脉粥样硬化事件（ILLUMINATE）试验的影响进行调查的影响，胆固醇酯转移蛋白抑制剂torcetrapib对血糖控制在6661糖尿病患者的试验。基线时，2个治疗组之间的血糖、胰岛素、血红蛋白A（1c）或胰岛素抵抗的稳态模型评估无差异。3个月后，联合使用托塞曲匹和阿托伐他汀的糖尿病受试者的血糖水平降低了0.34 mmol/L（P
Background-High-density lipoproteins have antidiabetic properties in vitro. Furthermore, elevated high-density lipoprotein levels accompanying a genetic deficiency of cholesteryl ester transfer protein are associated with decreased levels of plasma glucose. We now investigate effects on glucose homeostasis of inhibiting cholesteryl ester transfer protein with torcetrapib.Methods and Results-A post hoc analysis of the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial was conducted to investigate effects of the cholesteryl ester transfer protein inhibitor torcetrapib on glycemic control in the 6661 diabetic patients in the trial. At baseline, there were no differences between the 2 treatment arms with respect to plasma glucose, insulin, hemoglobin A(1c), or the homeostasis model assessment of insulin resistance. After 3 months, the diabetic subjects taking the combination of torcetrapib plus atorvastatin had plasma glucose levels 0.34 mmol/L lower (P